Evidence map›Paper›PMID 41963515›Full record

ArticleThe Journal of antibiotics2026

Tuspetinib enhances the activity of polymyxin B by inhibiting the GlcNAc6P deacetylase.

Yu Ouyang, Jinyong Zhang, Ruiqin Cui, Yini Huang, Dengpan Liang, Xinyue Wu, Xiaopeng Yuan, Xitao Li, Quanming Zou, Wei Huang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yu Ouyang *Department of Clinical Pharmacology, The First Affiliated Hospital of Anhui University of Science and Technology, Huainan, China.
Jinyong Zhang *National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University, Chongqing, China.
Ruiqin Cui *Department of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, China.
Yini HuangDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, China.
Dengpan LiangDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, China.
Xinyue WuDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, China.
Xiaopeng YuanDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, China.
Xitao LiSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China. lixt78@mail.sysu.edu.cn.
Quanming ZouNational Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University, Chongqing, China. qmzou2007@163.com.
Wei HuangDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, China. whuang_sz@163.com.ORCID http://orcid.org/0000-0002-8569-5184
Chao LuDepartment of Clinical Pharmacology, The First Affiliated Hospital of Anhui University of Science and Technology, Huainan, China. chaolu@aust.edu.cn.

Funding

Shenzhen Science and Technology Innovation Commission GJHZ20220913142800001
6 · The paper itself

Abstract

The past decade has witnessed the recognition of antibiotic resistance as an emerging threat to public health. Polymyxin B (PMB) is a last-resort antibiotic against multidrug-resistant (MDR) Gram-negative bacteria, but it has nephrotoxicity. A cocktail with molecules to sensitize microbes to PMB is an effective approach to rescue and expand its clinical application range. Tuspetinib (TUS) is a selective FMS-like tyrosine kinase 3 (FLT3) inhibitor with activity against acute myeloid leukemia (AML) and a favorable safety profile. In this study, we found that TUS can enhance the antibacterial activity of PMB against Klebsiella pneumoniae and its clinical PMB-resistant isolates. We also revealed the mechanism by which TUS inhibits the activity of GlcNAc6P deacetylase (NagA) and clarified the association between NagA and PMB resistance. Finally, we demonstrated the efficacy of TUS plus PMB therapy in a mouse model of pulmonary infection with a clinical PMB-resistant K. pneumoniae isolate. In all, this work discovers a promising drug combination strategy based on PMB and TUS and underlies the special mode of action that involves inhibiting the activity of NagA.

Indexed as

AmidohydrolasesAnti-Bacterial AgentsKlebsiella pneumoniaePolymyxin BAnimalsDisease Models, AnimalDrug Resistance, Multiple, BacterialDrug SynergismHumansKlebsiella InfectionsMiceMicrobial Sensitivity TestsAmidohydrolasesAnti-Bacterial AgentsPolymyxin B

Identifiers

PMID41963515

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.